格隆汇8月18日丨春立医疗(688236.SH)在互动平台表示，公司积极布局医疗器械科技前沿领域，目前， 髋关节手术机器人、膝关节手术机器人、单髁手术机器人等产品均已获得对应注册证。公司将持续融合 创新技术，驱动产品迭代与性能突破。 ...

本文源自：金融界 作者：公告君 金融界8月18日消息，有投资者在互动平台向春立医疗提问：公司在ai 医疗方面有啥创新和成绩。 公司回答表示：尊敬的投资者，您好！ 公司积极布局医疗器械科技前沿领域，目前，髋关节手术机器 人、膝关节手术机器人、单髁手术机器人等产品均已获得对应注册证。公司将持续融合创新技术，驱动 产品迭代与性能突破。感谢您的关注！ ...

Group 1 - The company is actively investing in cutting-edge medical device technology, focusing on surgical robots for hip and knee procedures [1] - The company has successfully obtained registration certificates for its hip joint surgical robot, knee joint surgical robot, and unicompartmental surgical robot [1] - The company aims to continuously integrate innovative technologies to drive product iteration and performance breakthroughs [1]

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][3][8]. Group 1: Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021 [7]. - The company's main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal implant products [8]. - The company has achieved a revenue composition of 99.92% from medical device products and 0.08% from other sources [8]. Group 2: Product Development and Innovation - The company has developed a range of orthopedic products, including hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2]. - Spring Medical is in the design and inspection phase for a customized porous tantalum dental implant product [2]. Group 3: Industry Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises [3]. Group 4: Financial Performance - For the period from January to March 2025, Spring Medical reported a revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.20% year-on-year [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [9]. Group 5: Market Activity - On August 13, the stock price of Spring Medical decreased by 0.04%, with a trading volume of 85.43 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 9.616 billion yuan [1]. - The stock has seen a net inflow of 669,900 yuan from major funds today, with a ranking of 29 out of 131 in its industry [4].